SAGE THERAPEUTICS INC. news, videos and press releases - Page 5
For more news please use our advanced search feature.
SAGE THERAPEUTICS INC. - More news...
SAGE THERAPEUTICS INC. - More news...
- Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
- Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
- Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
- Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer
- Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
- Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
- Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
- Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics to Present at Upcoming August Investor Conferences
- Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
- Sage Therapeutics to Present at Upcoming June Investor Conferences
- Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
- Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
- Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
- Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
- Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease
- Sage Therapeutics to Present at 2022 Stifel CNS Days
- Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
- Sage Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference
- Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD
- Sage Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
- Thinking about trading options or stock in Draftkings, Robinhood Markets, ViacomCBS, JinkoSolar, or SAGE Therapeutics?
- Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022
- Sage Therapeutics’ Third Annual FutureCast Showcases Data from All Three Brain Health Franchises
- Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
- Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
- Sage Therapeutics to Host Sage FutureCast Webcast
